🇺🇸

US SEC Filing Intelligence

· daily

US Earnings Financial Results SEC Filings — May 20, 2026

The 50 filings reveal a bifurcated market: growth companies like Analog Devices (+37% YoY revenue) and AEVEX Corp (swinging to $21M net income from a $27M loss) are thriving, while a broad swath of micro-cap and pre-revenue firms face severe liquidity crises, with 15+ companies reporting widening net losses and cash burn. Period-over-period trends show revenue growth concentrated in industrial, defense, and niche tech, while consumer-facing and energy-exposed firms struggle. Insider activity is sparse, but management teams at distressed companies are issuing dilutive securities at alarming rates. Capital allocation is defensive—debt reduction and equity raises dominate, with only a few firms (e.g., Immunovant) strengthening balance sheets via offerings. The most critical development is the wave of going-concern warnings and negative equity positions across 10+ filings, signaling potential bankruptcies. Portfolio-level patterns include margin compression in manufacturing (EnerSys -100 bps gross margin) and a surge in impairment charges (Heritage Distilling $62.1M, Haemonetics $86.5M).

50 high priority 50 total filings
· daily

US SEC Trading Suspension Halt Orders — May 20, 2026

The May 20, 2026 trading suspension intelligence stream reveals a concentrated cluster of 6 Nasdaq-listed micro-cap companies facing regulatory actions, with 50% of filings involving actual delisting notices (SOCIETY PASS, TOMI Environmental) and the remainder at various stages of non-compliance (Singularity Future, Socket Mobile, Aimei Health). This represents a significant escalation compared to prior periods, which typically saw 1-2 such events per day, indicating a potential tightening of Nasdaq enforcement or a broader distress cycle among sub-$1.00 micro-cap issuers. Period-over-period comparisons show that 4 of 6 companies have been non-compliant for over 6 months, with Singularity Future receiving its second 180-day extension—a pattern suggesting prolonged structural weakness rather than temporary volatility. No insider transactions were reported across any of the filings, which is notable given the severity of the events, implying management teams may be unable or unwilling to signal confidence through open-market purchases. The 3 companies with ongoing compliance periods (Socket Mobile, Singularity Future, Aimei Health) face deadlines between May and November 2026, creating a catalyst calendar for potential reversals or delistings. The complete absence of forward-looking financial guidance, capital allocation activity (dividends, buybacks), or positive operational metrics across all 6 filings paints a picture of entities in survival mode, with bankruptcy and illiquidity as material tail risks.

6 high priority 6 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — May 20, 2026

The 47 filings from May 20, 2026, reveal a bifurcated corporate landscape: a surge in distress signals (bankruptcies, delistings, liquidity crises) is concentrated in small-cap and pre-revenue tech/healthcare names, while larger, established firms are proactively refinancing debt and optimizing capital structures. Key period-over-period trends show a stark contrast, with companies like Curtiss-Wright reporting 12% YoY revenue growth but a 4.4% decline in net income, highlighting margin pressure, while Golden Minerals improved its net loss by 50% YoY but faces a severe cash crunch. The most critical developments include the Chapter 11 filing of Society Pass, multiple Nasdaq delisting notices (TOMI, Socket Mobile, Singularity Future), and a transformative but high-risk merger for Envirotech Vehicles. Portfolio-level patterns reveal a 'flight to quality' in debt markets, with investment-grade issuers like Gilead and Williams Companies accessing large, low-cost facilities, while distressed firms are forced into dilutive equity or debt-for-equity swaps. The overall market implication is one of increasing credit divergence, where access to capital is a key differentiator between survival and failure.

47 high priority 47 total filings
· daily

US Executive Officer Management Changes SEC — May 20, 2026

The 50 filings reveal a significant wave of leadership transitions across US equities, with CEO departures at Choice Hotels, NusaTrip, and Wendy's, alongside CFO changes at Philip Morris, Skillz, and Caleres, among others. Period-over-period data from ChoiceOne Financial shows adjusted net income dropping sharply to $1.0M in Q1 2026 from $28.2M in full-year 2025, signaling a concerning trend in regional banking performance. Insider activity is limited, but notable shareholder dissent on compensation plans at Iridium (13.2% against say-on-pay) and Insperity (7.7% against incentive plan) suggests governance tensions. Forward-looking guidance reaffirmations at Choice Hotels, Schrodinger, and Turtle Beach provide stability amid leadership changes, while BrightSpire Capital's CEO extension with reduced bonus targets signals a potential cost-control strategy. Capital allocation remains steady with dividend declarations at Iridium and Global Medical REIT, but the lack of buyback activity across filings suggests a cautious reinvestment posture. The most critical developments include the termination for cause of NusaTrip's CEO and CFO, which raises governance red flags, and the orderly succession at Clean Harbors with its founder retiring after 46 years. Overall, the digest points to a market in transition, with leadership changes concentrated in mid-cap and small-cap firms, requiring close monitoring of execution risks and strategic shifts.

50 high priority 50 total filings
· daily

US Corporate Board Director Changes SEC Filings — May 20, 2026

This batch of 50 filings covering the period May 20, 2026, reveals a significant wave of C-suite and board-level transitions, with CEO changes at major firms like Wendy's and Choice Hotels, and CFO appointments at Philip Morris, Skillz, and Caleres. The data shows a clear trend of companies appointing internal successors or returning former executives, suggesting a preference for continuity. Forward-looking statements, including reaffirmed guidance at Choice Hotels and Turtle Beach, indicate that leadership changes are not expected to disrupt near-term financial performance. Insider activity is limited, but the extension of CEO Michael Mazzei's contract at BrightSpire Capital with reduced compensation targets presents a unique mixed signal. Overall, the market is absorbing a high volume of governance changes, which could create volatility but also opportunities for investors focused on strategic realignment.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — May 20, 2026

The three filings reveal a bifurcated M&A landscape: strategic bolt-on acquisitions in defense tech (Red Cat/Quaze) and manufacturing capacity expansion (XPEL) contrast with a purely procedural SPAC unit separation (QDRO). Red Cat's acquisition of Quaze Technologies addresses a critical operational bottleneck in drone autonomy—wireless recharging—with immediate cross-domain applicability, while XPEL's $110M investment in US and China manufacturing capacity signals confidence in long-term demand, backed by reaffirmed mid-20% operating margin targets for 2028. The QDRO filing offers no financial or operational content, serving only as a reminder of the SPAC market's ongoing technical adjustments. Across the two material filings, both companies are deploying capital for growth rather than shareholder returns, with no dividends or buybacks disclosed. Insider trading activity was absent from all three filings, limiting conviction signals. The key portfolio-level theme is capital deployment into tangible assets (IP, facilities) to capture vertical integration and operational efficiency gains.

3 high priority 3 total filings
· monthly

US Pre-Market SEC Filings Roundup — May 20, 2026

Overnight filings reveal a bifurcated market, with high-growth tech and LPG shipping surging while traditional energy, real estate, and cash-burning pre-revenue companies deteriorate sharply. Period-over-period data shows Analog Devices leading with 37% revenue growth and 111% EPS expansion, while PrimeEnergy Resources saw a 52.5% net income decline. Insider activity is limited, but restructuring and M&A themes dominate: Select Medical's $16/share buyout, Sachem Capital's $3.4B industrial REIT combination, and Medline's secondary offering signal significant corporate activity. Several micro-cap companies (Cavitation Technologies, Cyber Enviro-Tech, Starfighters Space) face deepening losses and cash crunches. The most actionable themes are the semiconductor recovery (ADI +37% YoY, E20 Capital's $1.07B tech-heavy 13F), the LPG shipping boom (Dorian LPG +102% revenue), and the rising risk of delistings/bankruptcies in distressed micro-caps.

25 high priority 25 medium 50 total filings
· daily

NME Blockbuster Approvals — May 19, 2026

During the single-day period of May 19, 2026, the FDA issued one approval classified as 'Other' (FALLBACK type), with no NMEs, biosimilars, or label expansions recorded. The sole event was the NME approval of SONROTOCLAX (BEGALZI) from BEONE MEDICINES USA, granted Priority Review and Orphan Drug designations—a bullish signal for a rare disease asset. However, the lack of disclosed peak sales estimates, exclusivity terms, or pricing power limits the immediate commercial conviction. The dominant theme is a targeted rare disease NME launch, but the sparse approval volume offers no sector-wide therapeutic area clustering. Key watch items include the undisclosed market positioning and the absence of near-term catalysts beyond the approval itself.

1 total filings
· daily

Big Pharma Approvals — May 19, 2026

During this period, the FDA issued three label expansion approvals, all classified as 'FALLBACK' type, with zero NMEs, biosimilars, or standard label expansions. The dominant therapeutic area is immunology/inflammation, with Genentech Inc securing two approvals for its anti-PD-L1 franchise (TECENTRIQ HYBREZA and TECENTRIQ) and AstraZeneca AB obtaining one for its anti-IL-5Rα biologic FASENRA (benralizumab). The highest-conviction signal is the dual approval for Genentech's atezolizumab formulations, which strengthens its competitive position in oncology by offering both IV and subcutaneous delivery options. However, the lack of NME approvals and the 'FALLBACK' designation—which may indicate supplemental or minor label updates—limits the commercial upside and catalyst intensity. Key risk: without disclosed indication details or peak sales estimates, the materiality of these expansions remains uncertain, and investors should watch for payer coverage decisions and competitive dynamics in the PD-L1 and severe asthma markets.

3 total filings
· daily

Orphan Drug Approvals — May 19, 2026

This digest covers a single Orphan Drug Approval on May 19, 2026, with no NMEs, biosimilars, or label expansions recorded. The sole event is the FDA NME approval of SONROTOCLAX (BEGALZI) by BEONE MEDICINES USA, granted Priority Review and Orphan Drug designation, representing a high-conviction bullish signal for a novel therapy in a rare disease setting. The absence of other approvals limits therapeutic area clustering, but the single approval underscores BEONE MEDICINES USA's execution capability in bringing an NME to market with regulatory incentives. Key watch items include commercial launch dynamics and pricing strategy, as the drug’s peak sales and exclusivity details remain undisclosed, creating uncertainty around revenue potential.

1 total filings
· daily

New Drug Approvals (Original) — May 19, 2026

The May 19, 2026 FDA approval stream is dominated by biosimilar and generic approvals (11 of 12), with zero NMEs and one label expansion, signaling a period of market access expansion rather than novel drug innovation. The highest-conviction signal is the NME approval of SONROTOCLAX (BEGALZI) by BEONE MEDICINES USA, which received Priority Review and Orphan Drug designations, indicating a high-value, targeted therapy with strong regulatory endorsement. The biosimilar approval of GALLIUM GA-68 GOZOTETIDE by IONETIX via an unusual ANDA pathway introduces a lower-cost diagnostic alternative in the radiopharmaceutical space, bullish for the entrant but bearish for the undisclosed originator. The absence of NMEs and the high volume of biosimilar/generic approvals (10 of 12) suggest a market focus on cost containment and competitive erosion, with no new therapeutic area clusters emerging. Key watch items include the commercial launch of SONROTOCLAX and formulary access decisions for IONETIX’s diagnostic agent, as well as the IRA exposure of any small-molecule biosimilars approved this period.

12 total filings
· daily

New Federal Contractors — May 19, 2026

The sole contract recorded for May 19, 2026, is a $116.2M cost-plus-award-fee delivery order awarded to Booz Allen Hamilton by the General Services Administration (GSA) FEDSIM for civil-military support services. This is a civilian agency award with no defense-related component, and the aggregate obligation of $116.2M carries a neutral signal strength of 5/10. The contract's negative outlay (-$287K) and minimal subawards suggest negligible revenue recognized to date, limiting near-term financial impact. Key risks include award fee variability under cost-plus pricing and execution uncertainty given the low outlay, while the fully competed nature confirms Booz Allen's competitive positioning in professional support services.

1 total filings
· daily

Significant Contract Modifications ($10M+) — May 19, 2026

The single contract analyzed for May 19, 2026, is a $116.2M cost-plus-award-fee delivery order awarded to Booz Allen Hamilton by GSA FEDSIM for civil-military support services, representing a purely civilian obligation with zero defense exposure. The contract's neutral signal strength (5/10) and low materiality (3/10) are driven by a negative outlay (-$287K) and minimal subawards ($100K), indicating negligible revenue recognized to date and limited near-term financial impact. The award confirms sustained demand for interagency professional support services, but the cost-plus-award-fee structure introduces margin uncertainty tied to performance metrics. Key watch items include monitoring future outlay amounts to validate revenue recognition and tracking potential modifications beyond the March 2024 end date.

1 total filings
· daily

Contract Deobligations Alert — May 19, 2026

This digest covers a single $116.2M contract deobligation alert for Booz Allen Hamilton from the General Services Administration (GSA) FEDSIM, representing a civilian-sector award with zero defense exposure. The contract, a cost-plus-award-fee delivery order for civil-military support services, shows a negative outlay (-$287K) and minimal subawards ($100K), indicating limited revenue recognition to date and a neutral near-term financial impact. The highest-conviction signal is the lack of material revenue contribution, while the key risk is the award-fee variability tied to performance metrics. Investors should monitor future outlay adjustments to gauge contract execution and potential revenue realization.

1 total filings
· daily

Contract Option Exercises — May 19, 2026

The single contract digest for May 19, 2026, features a $116.2M cost-plus-award-fee delivery order awarded to Booz Allen Hamilton by the General Services Administration (GSA) FEDSIM for civil-military support services. This is a purely civilian award with no defense-related content, signaling stable demand for interagency professional support services but with a neutral investment signal due to a negative outlay (-$287K) indicating minimal revenue recognized to date. The contract's cost-plus pricing structure reduces downside risk but ties profit to performance metrics, creating margin uncertainty. The highest-conviction signal is the lack of near-term financial impact, as the negative outlay suggests deobligated funding or minimal work performed, making this a low-materiality event for investors. Key risk is the contract's March 2024 end date, which is already past, raising questions about extensions or modifications that are not reflected in the data.

1 total filings
· daily

Federal Professional Services Contracts — May 19, 2026

This single-contract digest covers a $116.2M cost-plus-award-fee delivery order awarded to Booz Allen Hamilton by GSA FEDSIM for civil-military support services, with zero defense-related contracts in the period. The contract is fully competed and not set aside, indicating Booz Allen won on merit, but the negative outlay (-$287K) and minimal subawards ($100K) suggest negligible revenue recognized to date, limiting near-term financial impact. The dominant theme is stable demand for professional support services in interagency coordination, though the cost-plus-award-fee structure introduces margin uncertainty. Key risk is the contract's March 2024 end date and potential for deobligation, while the neutral signal strength (5/10) and low materiality (3/10) reduce conviction for immediate investment action.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — May 19, 2026

The single contract in this period, a $116.2M cost-plus-award-fee delivery order awarded to Booz Allen Hamilton by GSA FEDSIM, is a civilian-sector award (0/1 defense-related) for civil-military support services. The contract carries a neutral signal with a low materiality score of 3/10, primarily due to a negative outlay (-$287K) suggesting minimal revenue recognized to date and potential deobligation of funds. While the award confirms Booz Allen’s competitive standing in professional support services, the contract type introduces margin uncertainty tied to performance metrics. The key risk is the lack of near-term revenue visibility, as the negative outlay implies limited financial impact through the March 2024 end date. Investors should monitor future outlay data and any modifications to assess revenue recognition and contract execution.

1 total filings
· daily

General Federal Contracts — May 19, 2026

This digest covers a single $116.2M cost-plus-award-fee delivery order awarded to Booz Allen Hamilton by GSA FEDSIM for civil-military support services through March 2024. The contract is fully civilian (0% defense-related) and represents a neutral signal with medium materiality. While the award confirms Booz Allen’s competitive strength in interagency professional support services, the negative outlay (-$287K) and minimal subawards ($100K) indicate negligible revenue recognition to date, limiting near-term financial impact. Key risks include award fee variability under cost-plus pricing and potential deobligation, while the primary watch item is future outlay data to confirm revenue ramp.

1 total filings